B Cell-specific Deficiency for Smad2 in Vivo Leads to Defects in TGF-beta-directed IgA Switching and Changes in B Cell Fate
Overview
Authors
Affiliations
Smad2 is a member of the intracellular mediators that transduce signals from TGF-beta receptors and activin receptors. Targeted inactivation of Smad2 in mice leads to early lethality before gastrulation. It was shown previously that TGF-betaRII deficiency in vivo leads to defects in B cell homeostasis, Ag responsiveness, and IgA class switch recombination of B cells. To investigate the importance of Smad2-mediated signaling in B lymphocytes, we generated a B cell-specific inactivation of Smad2 in mice (bSmad2(-/-)). bSmad2(-/-) mice had normal B cell numbers in the spleen but showed a reduced population of marginal zone B cells. In contrast, B cells in Peyer's patches and peritoneal B-1a cells of bSmad2(-/-) mice were increased in numbers. bSmad2(-/-) mice showed a reduced number of surface-IgA(+) B cells and of IgA-secreting cells in Peyer's patches, decreased levels of IgA in serum, and, after immunization with a T cell-dependent Ag, a reduced IgA response. Class switch recombination to IgA was impaired in Smad2-deficient B cells, when stimulated in vitro with LPS in the presence of TGF-beta. The growth-inhibitory effects of TGF-beta in LPS-stimulated B cells were not affected in Smad2-deficient B cells. In summary, our data indicate a crucial role of Smad2 in mediating signals for the TGF-beta-directed class switch to IgA and the induction of IgA responses in vivo. Other B cell functions like growth-inhibitory signaling, which are known to be regulated by signals via the TGF-betaR, are not affected in Smad2-deficient B cells.
Epithelial regulation of microbiota-immune cell dynamics.
Didriksen B, Eshleman E, Alenghat T Mucosal Immunol. 2024; 17(2):303-313.
PMID: 38428738 PMC: 11412483. DOI: 10.1016/j.mucimm.2024.02.008.
Timmins M, Ringshausen I Cancers (Basel). 2022; 14(7).
PMID: 35406544 PMC: 8996985. DOI: 10.3390/cancers14071772.
Gaignage M, Zhang X, Stockis J, Dedobbeleer O, Michiels C, Cochez P Cancer Immunol Immunother. 2022; 71(8):1851-1862.
PMID: 34973084 PMC: 9294018. DOI: 10.1007/s00262-021-03119-8.
Casali P, Li S, Morales G, Daw C, Chupp D, Fisher A Front Immunol. 2021; 12:761450.
PMID: 34868004 PMC: 8635144. DOI: 10.3389/fimmu.2021.761450.
Hogendorf A, Zielinski M, Constantinou M, Smigiel R, Wierzba J, Wyka K Front Immunol. 2021; 12:742834.
PMID: 34867966 PMC: 8637865. DOI: 10.3389/fimmu.2021.742834.